More: Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24,...
More: Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24,...
Link: BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
Go here to see the original: Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
Follow this link: HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Read the original: Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Read more from the original source: Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
Follow this link: Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
Read the original post: On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
More here: argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Read more here: Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders
Recent Comments